Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Scott Obach

Showing results (141-150 of 193) with videos related to

Pageof 20
Sort By:
Chemical Research in Toxicology|October 3, 2007
NADPH-dependent covalent binding of [3H]paroxetine to human liver microsomes and S-9 fractions: identification of an electrophilic quinone metabolite of paroxetineSabrina X Zhao, Deepak K Dalvie, Joan M Kelly, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 14, 2005
Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitroR Scott Obach, Anne E Reed-Hagen, Suzanne S Krueger, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 2, 2009
Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interactionOdette A Fahmi, Susan Hurst, David Plowchalk, et al.
Journal of Medicinal Chemistry|March 14, 2012
Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risksSuvi T M Orr, Sharon L Ripp, T Eric Ballard, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 16, 2002
Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitorsThanh Huu Tran, Lisa L Von Moltke, Karthik Venkatakrishnan, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 24, 2012
Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitorsRobert L Walsky, Jonathan N Bauman, Karine Bourcier, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 31, 2012
A novel relay method for determining low-clearance valuesLi Di, Patrick Trapa, R Scott Obach, et al.
Journal of Pharmaceutical Sciences|May 9, 2017
Professor Yuichi Sugiyama: A Brilliant, Creative, Amicable, Charming, and Humorous Pharmaceutical ScientistHiroyuki Kusuhara, R Scott Obach, Amin Rostami-Hodjegan, et al.
Chemical Research in Toxicology|January 17, 2009
Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolitesDeepak Dalvie, R Scott Obach, Ping Kang, et al.
Journal of Clinical Pharmacology|February 26, 2013
Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 2: clearanceFranco Lombardo, Nigel J Waters, Upendra A Argikar, et al.
Pageof 20

Showing results (141-150 of 193) with videos related to

Sort By:
Pageof 20
Chemical Research in Toxicology|October 3, 2007
NADPH-dependent covalent binding of [3H]paroxetine to human liver microsomes and S-9 fractions: identification of an electrophilic quinone metabolite of paroxetineSabrina X Zhao, Deepak K Dalvie, Joan M Kelly, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 14, 2005
Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitroR Scott Obach, Anne E Reed-Hagen, Suzanne S Krueger, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 2, 2009
Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interactionOdette A Fahmi, Susan Hurst, David Plowchalk, et al.
Journal of Medicinal Chemistry|March 14, 2012
Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risksSuvi T M Orr, Sharon L Ripp, T Eric Ballard, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 16, 2002
Microsomal protein concentration modifies the apparent inhibitory potency of CYP3A inhibitorsThanh Huu Tran, Lisa L Von Moltke, Karthik Venkatakrishnan, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 24, 2012
Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitorsRobert L Walsky, Jonathan N Bauman, Karine Bourcier, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|May 31, 2012
A novel relay method for determining low-clearance valuesLi Di, Patrick Trapa, R Scott Obach, et al.
Journal of Pharmaceutical Sciences|May 9, 2017
Professor Yuichi Sugiyama: A Brilliant, Creative, Amicable, Charming, and Humorous Pharmaceutical ScientistHiroyuki Kusuhara, R Scott Obach, Amin Rostami-Hodjegan, et al.
Chemical Research in Toxicology|January 17, 2009
Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolitesDeepak Dalvie, R Scott Obach, Ping Kang, et al.
Journal of Clinical Pharmacology|February 26, 2013
Comprehensive assessment of human pharmacokinetic prediction based on in vivo animal pharmacokinetic data, part 2: clearanceFranco Lombardo, Nigel J Waters, Upendra A Argikar, et al.
Pageof 20